# Retatrutide dosage: the trial step-ups · PepVault guides

Source: https://pepvault.app/guides/retatrutide-dosage-in-trials

Last updated: 2026-11-19

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Retatrutide dosage: the trial step-ups

Reviewed November 2026 12 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

- **Last reviewed:** Nov 19, 2026
- **Sources:** 12
- **Questions:** 7
- **Compounds:** 2

## The short answer

In the phase 3 TRIUMPH-1 and TRIUMPH-2 trials, retatrutide started at 2 mg once weekly and stepped up every four weeks, through 4, 6 and 9 mg, to a target of 4, 9 or 12 mg, so the top dose arrived at week 17. Phase 2 tested 0.5 to 12 mg, with climbs that started at 2 or 4 mg. These are research figures, not a dose for anyone.

Every number checked at its primary source · Nov 19, 2026 · [12 sources](https://pepvault.app/guides/retatrutide-dosage-in-trials#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Randomised phase 1b, phase 2 and phase 3 trials in people, published in The Lancet, NEJM and Nature Medicine, with the phase 3 step schedule and some figures from Lilly's releases and the TRIUMPH design paper; retatrutide is investigational and not approved.

## Why does retatrutide start low and climb?

Retatrutide is one peptide that works three hormone receptors: GIP, GLP-1 and glucagon[1](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-1). The first two are the incretin signals that turn appetite down, and GLP-1 also slows the stomach, so a meal feels bigger and lasts longer. That same action on the gut is where the common side effects come from, and they rise with the dose. In the phase 2 obesity trial the stomach effects were dose-related and mostly mild to moderate[1](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-1), and in its liver substudy they came mainly during the weeks of dose escalation[3](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-3).

So most arms in the trials climb to their dose rather than start there, and every arm in the TRIUMPH trials does[11](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-11). Phase 2's results record names the reason: the climb was there to improve stomach tolerability[2](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-2). The climb is slow for a second reason: retatrutide lasts. Its half-life in people is about six days, measured in a phase 1b trial[6](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-6). A drug with a six-day half-life takes roughly four to five half-lives, about a month of weekly doses, to settle at a steady level, which is about the length of each step the trials used. The chart shows that build-up.

Try it

How Retatrutide builds up

An estimate from a half-life of about 6.3 days, one dose a week for four weeks. The shape of the level, not a measurement.

[Try your own schedule](https://pepvault.app/tools/peptide-half-life-calculator) [Retatrutide in the library](https://pepvault.app/peptides/retatrutide)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What schedule did the phase 3 TRIUMPH trials use?

In TRIUMPH-1 and TRIUMPH-2, every arm started at 2 mg once weekly and stepped up every four weeks until it reached its target[7](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-7) [10](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-10). The target was assigned at random and kept blind, so neither the participants nor the staff knew who was climbing to which dose[11](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-11). The design paper describes it as a fixed escalation regimen: 16 weeks of escalation, then 64 weeks at the maintenance dose, for 80 weeks in all[11](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-11).

| Target dose | Steps on the way | Target reached |
| --- | --- | --- |
| 4 mg | 2 mg for four weeks | Week 5, after one step |
| 9 mg | 2, 4 and 6 mg, four weeks each | Week 13, after three steps |
| 12 mg | 2, 4, 6 and 9 mg, four weeks each | Week 17, after four steps |

The steps are Lilly's published description of the TRIUMPH-1 and TRIUMPH-2 schedule[7](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-7) [10](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-10); the week each target arrives follows from a step every four weeks. They describe the research, not a protocol to copy.

TRIUMPH-1 and TRIUMPH-2 tested all three targets against placebo. TRIUMPH-3, in people with established cardiovascular disease, and TRIUMPH-4, in people with knee osteoarthritis, tested 9 and 12 mg only[11](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-11). After week 80, TRIUMPH-1 ran a blinded 24-week extension for people with a BMI of 35 or more who had finished the 80 weeks and tolerated their assigned dose, in which everyone climbed to the highest dose they tolerated, 9 or 12 mg[7](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-7).

## What did the earlier trials test?

Phase 3 is the end of a search. The earlier trials tried lower and higher starts, smaller and bigger jumps, and fixed doses with no climb at all.

| Trial | Who, how long | Arms and their climbs |
| --- | --- | --- |
| Phase 1b, 2022[6](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-6) | 72 adults with type 2 diabetes, 12 weeks | Fixed 0.5, 1.5 and 3 mg; 3 then 6 mg; and 3, 6, 9 then 12 mg, the top doses reached by stepping up |
| Phase 2 obesity, 2023[1](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-1) [2](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-2) | 338 adults with obesity or overweight, 48 weeks | Fixed 1 mg; 4 mg from a 2 or a 4 mg start; 8 mg via 2 and 4 mg, or via 4 mg; 12 mg via 2, 4 and 8 mg |
| Phase 2 type 2 diabetes, 2023[4](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-4) [5](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-5) | 281 adults with type 2 diabetes, 36 weeks | Fixed 0.5 mg; 4 mg from a 2 mg start or with no climb; 8 mg via 2 and 4 mg, or via 4 mg; 12 mg via 2, 4 and 8 mg |
| TRIUMPH-1 and -2, 2026[7](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-7) [8](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-8) [9](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-9) [10](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-10) | 2,339 adults without diabetes, and 1,152 with type 2 diabetes, 80 weeks | 4, 9 or 12 mg, each from a 2 mg start, a step every four weeks |

In the phase 2 obesity trial, where a climb applied, the steps came every four weeks[3](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-3), and the last of them was done by week 12[2](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-2). Phase 2's ladder ran 2, 4, 8 and 12 mg. Phase 3 added smaller rungs at 6 and 9 mg, and its 12 mg arm takes four steps where phase 2's took three. The phase 2 diabetes paper says its results informed the dose selection for phase 3[4](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-4), and the TRIUMPH design paper says the doses and escalation were chosen from the phase 1 and 2 safety and efficacy data and exposure-response modelling[11](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-11).

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Incretin](https://pepvault.app/glossary/incretin)

## Does the starting dose make a difference?

Yes, and phase 2 measured it directly by running the same target dose from two different starts. The obesity trial's authors report that the stomach effects were partly eased by starting at 2 mg rather than 4 mg[1](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-1). The trial's posted results show the size of it, as the share of people who had nausea, in starting-dose arms of 33 to 35 people each[2](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-2):

- **4 mg target:** 18% with a 2 mg start, against 36% with a 4 mg start.
- **8 mg target:** 17% with a 2 mg start, against 60% with a 4 mg start.
- **Placebo:** 11%.

The diabetes trial saw the same pattern. Stomach effects ranged from 13% of people on the fixed 0.5 mg dose to 50% in the 8 mg arm that started at 4 mg, its fast climb, against 13% on placebo[4](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-4). Every arm in TRIUMPH-1 and TRIUMPH-2 opens at 2 mg[7](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-7) [10](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-10).

## What did each dose reach?

More dose bought more weight loss, with the gain shrinking toward the top. At 80 weeks in TRIUMPH-1, average weight loss was 17.6% on 4 mg, 23.7% on 9 mg and 25.0% on 12 mg, against 3.9% on placebo[8](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-8). Had everyone stayed on treatment (Lilly's efficacy estimand), the 4 mg arm, reached with a single step, averaged 19.0%[7](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-7). With type 2 diabetes, TRIUMPH-2 reached 11.9%, 16.8% and 18.8%, against 5.1% on placebo[9](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-9).

The same three doses were tested as a diabetes treatment in TRANSCEND-T2D-1, a 40-week trial in adults whose type 2 diabetes was not controlled by diet and exercise alone: HbA1c fell 1.69, 1.86 and 1.94 points against 0.81 on placebo, and weight fell 11.5%, 13.9% and 15.3% against 2.6%[12](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-12).

The higher targets also meant more people stopping. In TRIUMPH-1, 4.1% on 4 mg stopped because of side effects, close to placebo's 4.9%, against 6.9% on 9 mg and 11.3% on 12 mg[7](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-7). In TRIUMPH-2 the rates for stopping because of side effects or death were 4%, 12% and 8%, against 5% on placebo[9](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-9). The 4 mg arm traded some weight loss for a shorter climb and a stopping rate close to placebo's.

## What did the trials do when a step was hard?

The schedule was fixed, but it had a safety valve. In the TRIUMPH protocols, a person whose stomach effects or eating did not improve with other measures could step back down and then try the climb again. If that still failed, a permanent dose reduction was allowed. A reduction was also allowed for anyone who reached a BMI of 22 or less, or who felt they had lost too much weight[11](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-11).

The stomach effects themselves are the familiar ones of this drug class, and in TRANSCEND-T2D-1 they were generally mild to moderate and subsided over time[12](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-12). What helps in the step-up weeks is ordinary: smaller meals, eating slowly and stopping at the first sign of fullness, steady fluids through the day, and more fibre and water when constipation shows up.

**Commonly reported:** nausea or heavy fullness in the days after each step-up that settles within one to two weeks, appetite dropping early and further at each step, often described as stronger than on tirzepatide, and some tiredness.

## Is there an approved retatrutide dose?

No. Retatrutide is investigational, and Lilly states that it 'cannot be legally sold or marketed for human use'[10](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-10); it is legally available only to participants in Lilly's trials[7](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-7). Lilly plans to file with the FDA in the first quarter of 2027[10](https://pepvault.app/guides/retatrutide-dosage-in-trials#source-10).

That means there is no prescribing information yet: no approved starting dose, no approved step schedule, no official guidance on a missed dose or on restarting after a break. Those are the things a label exists to say, and a drug carries one only once a regulator has reviewed its trials and approved it. Until then, the schedules above are what retatrutide's dosing record consists of, each set and monitored by trial clinicians.

For the rest of the story, PepVault's guide to retatrutide week by week follows the same trials through appetite, weight and side effects, and the library page at pepvault.app/peptides/retatrutide covers how it works and its timeline.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. [PubMed 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/)
2. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Results record. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04881760)
3. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. [PubMed 38858523](https://pubmed.ncbi.nlm.nih.gov/38858523/)
4. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. [PubMed 37385280](https://pubmed.ncbi.nlm.nih.gov/37385280/)
5. ClinicalTrials.gov NCT04867785. A study of LY3437943 in participants with type 2 diabetes (phase 2; sponsor Eli Lilly and Company). Results record. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04867785)
6. Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. [PubMed 36354040](https://pubmed.ncbi.nlm.nih.gov/36354040/)
7. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html)
8. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. [PubMed 42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/)
9. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. [PubMed 42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/)
10. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. Press release, Sept 29, 2026. [prnewswire.com](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-substantial-weight-loss-and-a1c-reduction-underscoring-its-potential-promise-for-people-with-obesity-and-type-2-diabetes-302891798.html)
11. Giblin K et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. [PubMed 41090431](https://pubmed.ncbi.nlm.nih.gov/41090431/)
12. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a phase 3 trial. Lancet. 2026. [PubMed 42250575](https://pubmed.ncbi.nlm.nih.gov/42250575/)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)

What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Retatrutide Studied range: 1–12 mg](https://pepvault.app/peptides/retatrutide)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)

## Related guides

- Guide · GLP-1s

  ### [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)

  What to expect on retatrutide week by week: the trial dose steps, when appetite drops, weight loss at weeks 24, 48 and 80, and how side effects settle.

  Read the guide
- Guide · GLP-1s

  ### [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)

  What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Retatrutide

- [Retatrutide: the full reference](https://pepvault.app/peptides/retatrutide)
- [Retatrutide dose guide](https://pepvault.app/lab/dosage/retatrutide)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Retatrutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-5mg)
- [Retatrutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-10mg)
- [Retatrutide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-15mg)
- [Retatrutide 20 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-20mg)
- [Retatrutide 24 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-24mg)
- [Retatrutide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-30mg)
- [Retatrutide 40 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-40mg)
- [Retatrutide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/retatrutide-60mg)

### Studies

- [Retatrutide: systolic blood pressure down 6.79 mmHg in meta-analysis](https://pepvault.app/research/retatrutide-simental-mendia-2026)
- [Retatrutide: top odds of 15% or more weight loss across 19 trials](https://pepvault.app/research/retatrutide-sinha-2025)
- [Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials](https://pepvault.app/research/retatrutide-ruotolo-2026)
- [All 16 studies](https://pepvault.app/research#retatrutide)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Survodutide vs Retatrutide](https://pepvault.app/peptides/compare/survodutide-vs-retatrutide)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Mazdutide](https://pepvault.app/peptides/compare/retatrutide-vs-mazdutide)
- [Retatrutide vs Cagrilintide](https://pepvault.app/peptides/compare/retatrutide-vs-cagrilintide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it](https://pepvault.app/guides/aleniglipron-switch-trial)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [GIP](https://pepvault.app/glossary/gip)
- [Glucagon](https://pepvault.app/glossary/glucagon)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Incretin](https://pepvault.app/glossary/incretin)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
